NCT00712114View on ClinicalTrials.gov

Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

HE3286

HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.

DRUG

HE3286

HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days

DRUG

HE3286

HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days

Trial Locations (1)

90211

Beverly Hills

Sponsors
All Listed Sponsors
lead

Harbor Therapeutics

INDUSTRY